Keep the populations separate
The type 2 diabetes phase 2 study included 211 Chinese adults with T2D. It is distinct from the obesity trial, which excluded T2D. Enrollment, treatment arms, and outcomes from these studies should never be combined into one results table.
What the summary reports
Over 24 weeks, the study examined UBT251 2/4/6 mg regimens, semaglutide 1 mg, and placebo. These are trial protocol descriptions, not personal dosing instructions.
The summary reports HbA1c LS mean changes of −2.16% to −1.98% for UBT251, −1.77% for semaglutide, and −0.66% for placebo. This site preserves the supplied summary notation. It does not assign individual UBT251 values to particular arms because that mapping is not supplied in the locked extract.
What this overview does not establish
A numerical ordering in a summary does not establish superiority or non-inferiority. Without the full statistical contrasts and analysis context, readers should not convert these figures into comparative claims. The diabetes results do not replace the obesity trial’s weight endpoint.
Follow the companion sources
Read the companion Cell Metabolism paper. Registrations are NCT07163624 and CTR20250029. This overview deliberately stays within the supplied high-level facts; it does not invent adverse-event rates or secondary-outcome values.